Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $11.00.

A number of analysts have recently commented on the company. JMP Securities reissued a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $17.00 price target on the stock. Leerink Partners raised their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday.

Aquestive Therapeutics Trading Up 0.3 %

Shares of NASDAQ:AQST opened at $3.65 on Friday. The stock has a market capitalization of $332.80 million, a PE ratio of -8.11 and a beta of 2.62. The firm has a 50 day moving average of $4.71 and a 200-day moving average of $4.07. Aquestive Therapeutics has a 12 month low of $1.84 and a 12 month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. On average, research analysts predict that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in Aquestive Therapeutics by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock valued at $8,306,000 after purchasing an additional 90,543 shares during the period. State Street Corp lifted its position in Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after acquiring an additional 512,682 shares in the last quarter. Blue Owl Capital Holdings LP boosted its stake in Aquestive Therapeutics by 30.3% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after purchasing an additional 265,000 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in Aquestive Therapeutics by 4.9% during the 3rd quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock worth $4,598,000 after purchasing an additional 42,800 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $594,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.